|Tested species reactivity||Human, Mouse, Non-human primate, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide made to an N-terminal sequence of the human EGL9 homolog 1 (between residues 1-50). [LocusLink ID 54583]|
|Purification||Antigen affinity chromatography|
|Storage buffer||tris citrate, pH 7-8|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3 µg/ml|
|Immunohistochemistry (Paraffin) (IHC (P))||1:10-1:500|
|Western Blot (WB)||1:500-1:2500|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody does not react with mouse samples.
Suggested positive control: antigen standard for EGLN1 (transient overexpression lysate).
HIF prolyl hydroxylase 2 is a prolyl hydroxylase that modifies HIF-alpha. Classic prolyl hydroxylases are found in the endoplasmic reticulum and modify collagen, whereas HIF is an intracellular protein and the HPH sites do not resemble those modifying collagen. HIF is a transcriptional complex that plays a critical role in oxygen homeostasis. HPH is an essential component of the pathway through which cells sense oxygen. In the presence of oxygen, HPHs convert specific prolyl residues in HIF-alpha to hydroxyproline, leading to HIF-alpha destruction. Low oxygen levels, sensed at the cellular level, cause the HIF conversion to be reduced so that HIF is stable and there is increased angiogenesis. HPH-2, specifically, catalyzes the posttranslational formation of 4-hydroxyproline in HIF alpha proteins. It hydroxylates HIF-1 alpha at Pro(402) and Pro(564), and HIF-2 alpha. It targets HIF through the hydroxylation for proteasomal degredation via the von Hippel-Lindau ubiquitylation complex.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.